WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H525005
CAS#: 80879-63-6
Description: Emiglitate, a deoxynojirimycin derivative, is an α-glucosidase inhibitor that is a powerful inhibitor of glucose-induced insulin release.
Hodoodo Cat#: H525005
Name: Emiglitate
CAS#: 80879-63-6
Chemical Formula: C17H25NO7
Exact Mass: 355.16
Molecular Weight: 355.380
Elemental Analysis: C, 57.45; H, 7.09; N, 3.94; O, 31.51
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: Emiglitate; Emiglitate [INN:BAN]; Emiglitatum; BAY o 1248; EINECS 279-613-2;Emiglitatum [Latin]; Emiglitate; UNII-PF8AB2IBUM.
IUPAC/Chemical Name: 1,5-Dideoxy-1,5-((2-(4-(ethoxycarbonyl)phenoxy)ethyl)imino)-D-glucitol
InChi Key: NWWORXYTJRPSMC-CAOSSQGBSA-N
InChi Code: InChI=1S/C17H25NO7/c1-2-24-17(23)11-3-5-12(6-4-11)25-8-7-18-9-14(20)16(22)15(21)13(18)10-19/h3-6,13-16,19-22H,2,7-10H2,1H3/t13-,14-,15+,16+/m0/s1
SMILES Code: C1[C@@H]([C@@H](O)[C@@H]([C@H](CO)[N@@]1CCOc1ccc(cc1)C(OCC)=O)O)O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not in water
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 355.38 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Mosén H, Salehi A, Henningsson R, Lundquist I. Nitric oxide inhibits, and carbon monoxide activates, islet acid alpha-glucoside hydrolase activities in parallel with glucose-stimulated insulin secretion. J Endocrinol. 2006 Sep;190(3):681-93. PubMed PMID: 17003269.
2: Depre C, Hue L. Inhibition of glycogenolysis by a glucose analogue in the working rat heart. J Mol Cell Cardiol. 1997 Aug;29(8):2253-9. PubMed PMID: 9281456.
3: Lundquist I, Panagiotidis G, Salehi A. Islet acid glucan-1,4-alpha-glucosidase: a putative key enzyme in nutrient-stimulated insulin secretion. Endocrinology. 1996 Apr;137(4):1219-25. PubMed PMID: 8625892.
4: Salehi A, Lundquist I. Modulation of islet G-proteins, alpha-glucosidehydrolase inhibition and insulin release stimulated by various secretagogues. Biosci Rep. 1996 Feb;16(1):23-34. PubMed PMID: 8861537.
5: Salehi A, Panagiotidis G, Borg LA, Lundquist I. The pseudotetrasaccharide acarbose inhibits pancreatic islet glucan-1,4-alpha-glucosidase activity in parallel with a suppressive action on glucose-induced insulin release. Diabetes. 1995 Jul;44(7):830-6. PubMed PMID: 7789651.
6: Bischoff H. Pharmacology of alpha-glucosidase inhibition. Eur J Clin Invest. 1994 Aug;24 Suppl 3:3-10. Review. PubMed PMID: 8001624.
7: Salehi A, Lundquist I. Changes in islet glucan-1,4-alpha-glucosidase activity modulate sulphonylurea-induced but not cholinergic insulin secretion. Eur J Pharmacol. 1993 Oct 19;243(2):185-91. PubMed PMID: 8276068.
8: Salehi A, Lundquist I. Islet glucan-1,4-alpha-glucosidase: differential influence on insulin secretion induced by glucose and isobutylmethylxanthine in mice. J Endocrinol. 1993 Sep;138(3):391-400. PubMed PMID: 7506286.
9: Lembcke B, Fölsch UR, Gatzemeier W, Lücke B, Ebert R, Siegel E, Creutzfeldt W. Inhibition of sucrose- and starch-induced glycaemic and hormonal responses by the alpha-glucosidase inhibitor emiglitate (BAY o 1248) in healthy volunteers. Eur J Clin Pharmacol. 1991;41(6):561-7. PubMed PMID: 1815967.
10: Lembcke B, Lamberts R, Wöhler J, Creutzfeldt W. Lysosomal storage of glycogen as a sequel of alpha-glucosidase inhibition by the absorbed deoxynojirimycin derivative emiglitate (BAYo1248). A drug-induced pattern of hepatic glycogen storage mimicking Pompe's disease (glycogenosis type II). Res Exp Med (Berl). 1991;191(6):389-404. PubMed PMID: 1775731.
11: Dimitriadis G, Hatziagelaki E, Ladas S, Linos A, Hillebrand I, Raptis S. Effects of prolonged administration of two new alpha-glucosidase inhibitors on blood glucose control, insulin requirements and breath hydrogen excretion in patients with insulin-dependent diabetes mellitus. Eur J Clin Invest. 1988 Feb;18(1):33-8. PubMed PMID: 3130257.
12: Serrano-Rios M, Sabán J, Navascués I, Cañizo JF, Hillebrand I. Effect of two new alpha-glucosidase inhibitors in insulin-dependent diabetic patients. Diabetes Res Clin Pract. 1988 Jan 7;4(2):111-6. PubMed PMID: 3277827.
13: Gerard J, Hillebrand I, Lefèbvre PJ. Assessment of the clinical efficacy and tolerance of two new alpha-glucosidase inhibitors in insulin-treated diabetics. Int J Clin Pharmacol Ther Toxicol. 1987 Sep;25(9):483-8. PubMed PMID: 3316059.
14: Kennedy FP, Miles JM, Heiling V, Gerich JE. The effect of two new alpha-glucosidase inhibitors on metabolic responses to a mixed meal in normal volunteers. Clin Exp Pharmacol Physiol. 1987 Aug;14(8):633-40. PubMed PMID: 3326689.
15: Federlin KF, Mehlburger L, Hillebrand I, Laube H. The effect of two new glucosidase inhibitors on blood glucose in healthy volunteers and in type II diabetics. Acta Diabetol Lat. 1987 Jul-Sep;24(3):213-21. PubMed PMID: 3687313.
16: Omar MA, Seedat MA, Hillebrand I. The clinical efficacy of a second-generation alpha-glucosidase inhibitor in non-insulin-dependent diabetic patients. S Afr Med J. 1987 Apr 4;71(7):422-3. PubMed PMID: 2951875.
17: Hillebrand I. Pharmacological modification of digestion and absorption. Diabet Med. 1987 Mar-Apr;4(2):147-50. PubMed PMID: 2952432.
18: Lembcke B, Löser C, Fölsch UR, Wöhler J, Creutzfeldt W. Adaptive responses to pharmacological inhibition of small intestinal alpha-glucosidases in the rat. Gut. 1987;28 Suppl:181-7. PubMed PMID: 3319810; PubMed Central PMCID: PMC1434562.
19: Lee SM, Bustamante S, Flores C, Bezerra J, Goda T, Koldovský O. Chronic effects of an alpha-glucosidase inhibitor (Bay o 1248) on intestinal disaccharidase activity in normal and diabetic mice. J Pharmacol Exp Ther. 1987 Jan;240(1):132-7. PubMed PMID: 3100764.
20: Samulitis BK, Goda T, Lee SM, Koldovský O. Inhibitory mechanism of acarbose and 1-deoxynojirimycin derivatives on carbohydrases in rat small intestine. Drugs Exp Clin Res. 1987;13(8):517-24. PubMed PMID: 2962844.
